Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Quantum Genomics Société Anonyme (ALQGC.PA)

Paris - Paris Delayed Price. Currency in EUR
0.1421-0.0019 (-1.32%)
At close: 05:35PM CET
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1440
Open0.1455
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1400 - 0.1480
52 Week Range0.1385 - 4.4980
Volume77,345
Avg. Volume723,608
Market Cap4.907M
Beta (5Y Monthly)0.06
PE Ratio (TTM)N/A
EPS (TTM)-0.6030
Earnings DateOct 05, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.59
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ALQGC.PA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, FRESH and is Redirecting to New Developments

      Firibastat efficacy non-significant versus placeboThe REFRESH study and the development of firibastat in cardiology have been stoppedCash of 11 million euros allotted to the development of new innovative treatments, after discontinuation of the REFRESH study PARIS, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medications that directly target the brain to treat resistant h

    • Zacks Small Cap Research

      ALQGC.PA: First Half Results

      By John Vandermosten, CFA EPA:ALQGC READ THE FULL ALQGC.PA RESEARCH REPORT Quantum Genomics S.A. (EPA:ALQGC) reported first half 2022 results in an October 5 th press release . During the period, Quantum enrolled its final patient in the FRESH study and has scheduled the release of topline results to be presented at the American Heart Association November conference in Chicago, Illinois. Other

    • GlobeNewswire

      Bryan Garnier & Co Initiates the Coverage of Quantum Genomics with a Target Price at 13€ per Share

      PARIS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specialising in the development of a new class of medicinal products that act directly on the brain to treat resistant/difficult to treat hypertension and heart-failure, today announces the publication of an initiation report by Bryan Garnier & Co, a pan-European investment bank focusing on growth companies. With the initiation report entitled “The shape of my heart”, p

    Advertisement
    Advertisement